Omnipod® 5 Automated Insulin Delivery System
Omnipod 5 is a wearable, tubeless, hybrid closed loop system that integrates with the leading sensor brands, for people with type 1 diabetes aged 2 years and older requiring insulin. It will be available for your patients in 2026.
Three Simple Parts
Controller + Pod + Sensor*
Omnipod 5 Controller
The Omnipod 5 Controller allows you to monitor and control the Pod using Bluetooth® wireless technology.
Pod
Tubeless, wearable, and waterproof,** the Pod, with built-in SmartAdjust™ technology, sits right on your patient’s body and automatically§ adjusts insulin delivery for up to 3 days (72 hours).
§Automated Mode requires compatible CGM/Sensor
**The Pod has an IP28 rating for up to 7.6 metres for up to 60 minutes. The Omnipod 5 Controller is not waterproof. Please consult sensor manufacturer user guide for sensor waterproof rating.
Sensor
Continuously sends glucose values to the Pod, so your patients can get the real-time dataƗ without the finger pricks†.
†Fingerpricks required for diabetes treatment decisions if symptoms or expectations do not match readings.
SmartAdjust™ so you don’t have to!1
Omnipod 5 with SmartAdjust™ technology automatically adjusts to your patients’ personal needs by increasing, decreasing, or pausing insulin delivery every five minutes – which may help prevent highs and lows.2,3
Diabetes Data Management, Simplified
Omnipod Discover is a simplified diabetes data management system that lets you and your Omnipod 5 patients see how their pump setting and bolus behavior is impacting their blood glucose levels—empowering you to develop diabetes management strategies together.
Find answers to the most frequently asked questions on Omnipod 5
What is Omnipod 5?
How does Omnipod 5 differ from Omnipod DASH®?
When will Omnipod 5 be available in Kuwait?
Who can use Omnipod 5?
*Sensors are sold separately and each require a separate prescription.
1.In Automated Mode, SmartAdjust™ technology uses your total daily insulin (TDI) to set a new Adaptive Basal Rate for you. Requires a compatible sensor. Compatible sensor prescribed and sold separately.
2. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in hyperglycaemic range (>10.0 mmol/L or >180mg/dL) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 28.9% vs. 22.8%; 44.8% vs 29.7%, P<0.0001, respectively. Mean time in hypoglycaemic range (<3.9 mmol/L or <70 mg/dL) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 2.89% vs. 1.32%, P<0.0001; 2.21% vs. 1.78, P=0.8153, respectively.
3. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-day standard therapy (ST) phase followed by a 3-month AID phase with Omnipod 5 system. Mean time in hyperglycaemic range (>10.0 mmol/L or Stay in the know! Sign up here to get the latest news and updates. Find answers to the most frequently asked questions on Omnipod 5 >180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 39.4% vs. 29.5%, P<0.0001, respectively. Mean time in hypoglycaemic range (<3.9 mmol/L or <70 mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 3.43% vs. 2.46%, P=0.0204.
Important Safety Information: The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with NovoLog®/NovoRapid®, Humalog® /Liprolog ®, Trurapi®/Truvelog®/Insulin aspart Sanofi®, Kirsty®, and Admelog/Insulin lispro Sanofi U-100 insulin. Warning: SmartAdjust technology should not be used by anyone under the age of 2 years old or by people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population.
Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide and www.omnipod.com/en-gb/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions.